MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
Introduction In this secondary analysis of the Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment (MARCH) trial, we evaluated what demographic and clinical factors were associated with reduction in weight. We also assessed the effects of acarbose and metformin treatment on weig...
Guardado en:
Autores principales: | Na Wang, Jin-Ping Zhang, Xiao-Yan Xing, Zhao-Jun Yang, Bo Zhang, Xin Wang, Wen-Ying Yang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Termedia Publishing House
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f47e2d59273c4b97bcd307641ba863bb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome
por: Nielson T. Baxter, et al.
Publicado: (2019) -
Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes
por: Song L, et al.
Publicado: (2021) -
A Combination Approach in Inhibiting Type 2 Diabetes-Related Enzymes Using <i>Ecklonia radiata</i> Fucoidan and Acarbose
por: Blessing Mabate, et al.
Publicado: (2021) -
Metformin action over gut microbiota is related to weight and glycemic control in gestational diabetes mellitus: A randomized trial
por: María Molina-Vega, et al.
Publicado: (2022) -
Principles of Rapid Weight Loss in Female Sambo Athletes
por: Nikola Todorović, et al.
Publicado: (2021)